Medi-Cal Rx Transition — Compliance and Reimbursement Impacts
Pharmacy benefit transition goes live on Jan. 1, 2022, and this webinar to feature Q&A with DHCS and Magellan Health.
Hospital Fee Program (7) Status Update
Ryan Witz, CHA’s Group Vice President, Policy, will share insights on the length of the program as well as base year data to be used for modeling and more.
CHA Issues Summary of FFY 2022 Inpatient Prospective Payment System Final Rule
CHA has issued a detailed summary of the federal fiscal year (FFY) 2022 inpatient prospective payment system (IPPS) final rule. The policy and payment provisions in the final rule are effective for FFY 2022 discharges, beginning Oct. 1.
CHA Comments on CY 2022 OPPS Proposed Rule
CHA has submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the calendar year 2022 outpatient prospective payment system (OPPS) proposed rule.
CHA Issues Draft Comments on CY 2022 Outpatient Prospective Payment System Proposed Rule
CHA has issued a members-only copy of draft comments on the calendar year (CY) 2022 outpatient prospective payment system (OPPS) proposed rule. CHA encourages members to use the draft as a template for their own comments, which are due to the Centers for Medicare & Medicaid Services (CMS) by 2 p.m. (PT) on Sept. 17.
CHA Issues Detailed Summary of CY 2022 OPPS Proposed Rule
CHA has issued a detailed summary of the calendar year (CY) 2022 outpatient prospective payment system (OPPS) proposed rule. Comments are due to the Centers for Medicare & Medicaid Services (CMS) by 2 p.m. (PT) on Sept. 17.
Supreme Court Will Hear Case Challenging Medicare’s 340B Payment Cuts
On July 2, the Supreme Court agreed to hear American Hospital Association v. Becerra, a case that challenges Medicare’s 22.5% payment reduction to hospitals for certain separately payable outpatient drugs acquired under the 340B program.
HHHS Withdraws Guidance Requiring Manufacturers to Provide 340B Discount at Contract Pharmacies
The Department of Health & Human Services (HHS) has withdrawn a December 2020 advisory opinion from the Health Resources and Services Administration requiring pharmaceutical manufacturers to sell covered entities 340B drugs at or below the ceiling price when those drugs are distributed through a contract pharmacy. Earlier this year, AstraZeneca and other drugmakers sued the agency over the opinion. The withdrawal follows a federal judge denying HHS’ request to dismiss AstraZeneca’s challenge.
CHA Alert Urges Congress to Protect Program Eligibility for 340B Hospitals During COVID-19 PHE
On June 9, CHA issued an alert asking hospitals to urge their U.S. senators and representatives to support bipartisan legislation that preserves program eligibility for certain 340B hospitals during the COVID-19 public health emergency.
CHA Issues FFY 2022 Inpatient Prospective Payment System Proposed Rule Summary
CHA has issued a detailed summary of the federal fiscal year (FFY) 2022 inpatient prospective payment system proposed rule issued by the Centers for Medicare & Medicaid Services (CMS). Comments are due to CMS by 2 p.m. (PT) on June 28 and can be submitted electronically by searching for file code “CMS-1752-P.”